Phanes’ spevatamig shows 40% response rate in mPDAC: How it compares to GnP standard
Phanes’ spevatamig + chemo combo shows 40% ORR in mPDAC. Find out why this bispecific antibody may change frontline pancreatic cancer treatment.
Aktis Oncology raises $318m IPO: What this means for alpha radiotherapy biotech bets
Can Aktis Oncology’s IPO jumpstart alpha radiopharma? Find out what its $318M raise means for solid tumor treatment and VC-to-IPO biotech strategy.
Can functional logic beat genetic drift? MindWalk’s bet on influenza physics
MindWalk says flu can’t mutate past this. Find out how its HYFT AI platform found a functional constraint that may redefine universal vaccine design.
Pfizer’s BRAFTOVI triplet shows 64% response in first-line BRAF-mutant colorectal cancer
Pfizer’s BRAFTOVI triplet hit a 64% response rate in BRAF-mutant colorectal cancer. Find out what this could mean for first-line treatment standards.
Can Kinaset’s inhaled JAK inhibitor finally bring relief to all severe asthma patients?
Kinaset raises $103M to advance frevecitinib, a novel inhaled JAK inhibitor for severe asthma. Find out what makes this candidate different.
Camurus’s FDA review restart for Oclaiz puts long-acting octreotide on track for a potential U.S. launch in mid-2026
Camurus AB announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of the New Drug Application for Oclaiz (CAM2029), an extended-release octreotide injection for acromegaly. The agency assigned a Prescription Drug User Fee Act (PDUFA) action date of June 10, 2026, reinitiating regulatory review after an earlier Complete Response Letter related […]
J&J’s amivantamab shows strong first-line response in metastatic colorectal cancer
Johnson & Johnson (J&J) has reported updated results from its Phase 1b/2 OrigAMI-1 trial evaluating amivantamab-vmjw in combination with chemotherapy for patients with RAS/BRAF wild-type metastatic colorectal cancer. The bispecific antibody, which targets epidermal growth factor receptor (EGFR) and MET, achieved confirmed response rates of 73 percent in the first-line setting and 44 percent in […]
Ollin’s next-gen VEGF/Ang2 antibody shows superiority over faricimab in Phase 1b trial
Ollin’s OLN324 outperformed faricimab in a head-to-head retinal trial. Find out how this could change first-line treatment in DME and wAMD.
Can SonoThera’s RIPPLE platform redefine nonviral delivery in oversized genetic payloads?
Can SonoThera’s ultrasound platform reshape gene therapy delivery? Find out how its $125M Series B targets DMD, ADPKD, and XLAS with nonviral precision.
Will Surf’s SUSTAIN platform bring at-home neuromodulation to mainstream rheumatology?
Surf begins human trial for ultrasound-based neuromodulation in RA. Can it challenge biologics? Find out what this means for autoimmune therapy access.